Bio Blast Pharma, a biotech developing treatments for rare and ultra-rare genetic diseases, raised $35 million by offering 3.2 million shares at $11, the low end of the range of $11 to $13. Bio Blast Pharma plans to list on the NASDAQ under the symbol ORPN. Oppenheimer & Co. and Roth Capital acted as lead managers on the deal.
